SEVERE ADULT ATOPIC DERMATITIS
CLINICAL TRIAL | the abstract
Principal Investigator: Dr. Jennifer Cather
A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of DUPIXENT® (dupilumab) in adult patients with moderate-to-severe atopic dermatitis.
DUPIXENT® (dupilumab) is an injectable biologic which targets IL4 and IL13, both of which play a vital role in atopic dermatitis. The study compared two different doses of DUPIXENT® to evaluate skin clearance, quality of life improvements, and safety. Skin clearance was associated with improvements in quality of life. Additionally, itch, sleep, and the number of days requiring topical therapies decreased while on DUPIXENT® (dupilumab).
DUPIXENT® (dupliumab) is approved for adolescents and adults with atopic dermatitis. As seen in this clinical trial experience, even on DUPIXENT® (dupilumab) patients may not be symptom-free and residual dermatitis or areas of new dermatitis on therapy may require add-on therapies—by mouth or topical.
SOTA Formula Consideration Based on Data:
Topical and oral CBD helps treat atopic dermatitis. There are case reports of topical CBD improving atopic dermatitis. Oral use of CBD may help with itch and pain associated with the disease. Learn more about the benefits of SOTA Topicals and Tinctures.
Study dates: 2015-2016